Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 7, 2006, Pages 1014-1019

  Ruggeri, Rosaria Maddalena ^a   Sciacchitano, Salvatore ^b,c   Vitarelli, Enrica ^a   Trimarchi, Francesco ^a   Barresi, Gaetano ^a   Trovato, Maria ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CELL COUNT; CELL POPULATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; THYROID MEDULLARY CARCINOMA; UPREGULATION;

ADULT; AGED; CARCINOMA, MEDULLARY; CELL COUNT; CYCLOOXYGENASE 2; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 33745961871     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol. 1989;9:3808-3820.
2. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol. 1997;160:161-175.
3. Johnstone RW, Ruefli AA, Smyth MJ. A family of drug transporters: the multidrug resistance-associated proteins. Trends Biochem Sci. 2000;25:1-6.
4. Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors. 2003;17:103-114.
5. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295-1302.
6. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCC2) in tissue defense. Toxicol Appl Pharmacol. 2005;204:216-237.
7. Fernandez SB, Hollo Z, Kern A, et al. Role of the N-terminal transmembrane region of the multidrug resistance protein MRP2 in routing to the apical membrane in MDCKII cells. J Biol Chem. 2002;277:31048-31055.
8. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999;55:929-937.
9. Koike K, Kawabe T, Tanaka T, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997;57:5475-5479.
10. Gaumann A, Tews DS, Mentzel T, et al. Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch. 2003;442:529-537.
11. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157-33160.
12. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
13. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
14. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
15. McGinty A, Chang YW, Sorokin A, Bokemeyer D, Dunn MJ. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem. 2000;275:12095-12101.
16. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004;45:47-54.
17. Ratnasinghe D, Daschner PJ, Anver MR, et al. Cyclooxygenase-2, glycoprotein-170 and drug resistance: is chemoprevention against multidrug resistance possible? Anticancer Res. 2001;21:2141-2147.
18. Saikawa Y, Sugiura T, Toriumi F, et al. Cyclooxygenase-2 induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res. 2004;24:2723-2728.
19. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des. 2004;10:647-657.
20. Larsson R, Nygren P. Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein. Cancer Lett. 1990;54:125-131.
21. Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in human medullary thyroid carcinoma cell line: association with overexpression of mdr1 gene and low proliferation fraction. Anticancer Res. 1991;11:1065-1068.
22. Schlumberger M, Cardet P, De Vathaire F, Sarrazin D, Travagli JP, Parmentier C. External radiotherapy and chemotherapy in MTC patients. In: Calmettes C, Culiana JM, eds. Medullary Thyroid Carcinoma. Paris, France: Colloque INSERM/John Libbey, Eurotext Ltd; 1991;211:213-220.
23. Schlumberger M, Pacini F. Medullary thyroid carcinoma. In: Thyroid Tumors. 2nd ed. Paris, France: Nucleon; 2003:267-299.
24. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5FU-dacarbazine. Br J Cancer. 2000;83:715-718.
25. Orlandi F, Caraci P, Mussa E, Saggiorato G, Pancani G, Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001;8:135-147.
26. Specht MC, Tucker ON, Hocever M, Gonzales D, Teng L, Fahey TJ III. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab. 2002;87:358-363.
27. Nose F, Ichikawa T, Fujiwara M, Okayasu I. Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am J Clin Pathol. 2002;117:546-551.
28. Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope. 2002;112:238-242.
29. Ito Y, Yoshida H, Nakano K, et al. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology. 2003;42:492-497.
30. Casey MB, Zhang S, Jin L, Kajita S, Lloyd RV. Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions. Endocrinol Pathol. 2004;15:107-116.
31. Lo CY, Lam KY, Leung PP, Luk JM. High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. Eur J Endocrinol. 2005;152:545-550.
32. Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV. Role of COX-2, thromboxane A2 synthase, and prostaglandin 12 synthase in papillary thyroid carcinoma growth. Mod Pathol. 2005;18:221-227.
33. Haynik DM, Prayson RA. Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid. Arch Pathol Lab Med. 2005;129:736-741.
34. Garcia-Gonzales M, Abdulkader I, Boquete AV, Neo XM, Forteza J, Cameselle-Teijeiro J. Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland. Virchows Arch. 2005;447:12-17.
35. Bell CD, Vidal S, Kovacs K, Horvath E, Rotondo F. An immunohistochemical survey of nine cases of medullary carcinoma of thyroid including reactivity for cox-1 and cox-2 enzymes. Endocr Pathol. 2002;13:331-340.
36. Kim SJ, Lee JH, Yoon JS, et al. Immunohistochemical expression of COX-2 in thyroid nodules. Korean J Intern Med. 2003;18:225-229.
37. Rosai J, Carcangiu ML, De Lellis R. Tumors of the thyroid gland. Washington, DC: Armed Forces Institute of Pathology; 1992:207-245. Atlas of Tumor Pathology, 3rd series, fascicle 5.
38. Hermanek P, Sobin LH, eds. Thyroid gland (ICD-OC73). In: TNM Classification of Malignant Tumors. 6th ed. New York, NY: International Union Against Cancer/Springer-Verlag; 2002:89-98.
39. Gown AM, deWever N, Battifora H. Microwaved-based antigen unmasking: a revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem. 1993;1:256-266.
40. Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003;38:717-727.
41. Modigliani E, Cohen R, Campos MJ, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol. 1998;48:265-273.
42. Kebebew E, Ituarte P, Siperstein A, Duh QY, Clark O. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
43. Hyer SL, Vini L, A'Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol. 2000;26:686-690.
44. Scherubl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer: phase II study. J Cancer Res Clin Oncol. 1990;116:21-23.
45. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid carcinoma with an alternating combination of 5FU-streptozocin and 5FU-dacarbazine. Br J Cancer. 1995;71:363-365.
46. Massart C, Gibassier J, Raoul M, et al. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anticancer Drugs. 1995;6:135-146.
47. Massart C, Gibassier J, Denais A, Genetet N. Effect of PSC 833 on the efficacy of doxorubicin in vitro in a medullary thyroid carcinoma cell line. Anticancer Res. 1998;18:2953-2956.